

Guideline 14.1 – Acute Coronary Syndromes: Presentation

Guideline

Who does this guideline apply to?

This guideline applies to adult victims.

Who is the audience for this guideline?

This guideline is for use by first responders and health professionals.

1.0 | Symptoms and Signs

While it is important that patients who are at risk and their families should be able to recognise characteristic symptoms that may be indicative of ACS, it is important to note that signs and symptoms alone are neither sufficiently sensitive nor specific. (LOE IV). (See [Guideline 9.2.1 Chest Pain](#))

Even amongst trained health care providers, signs and symptoms alone should not be used without other information for making the diagnosis of ACS^{1,2}. (LOE IV) Signs and symptoms may be useful when used in combination with other information such as biomarkers, risk factors, an ECG and other diagnostic tests, in making triage and some treatment decisions in the out of hospital and emergency department (ED) setting.

A cautionary note also applies to the use of a response to sublingual nitroglycerine therapy as a diagnostic manoeuvre³⁻⁶. Although it is reasonable to consider nitroglycerine in select patients without contraindications, there is really insufficient data to recommend relief of chest pain with nitroglycerine as a diagnostic test for ACS. (LOE IV)

There are various patient related factors which impede seeking medical help. These factors include older age, belonging to racial and ethnic minorities, female gender, lower social status and social isolation⁷⁻¹³. This is particularly important to recognise these issues when providing

care to the Australian indigenous, Maori and Pacific Islander population. (LOE IV) It is important that the health care providers are trained to expeditiously identify ACS irrespective of these factors.

2.0 | The 12 Lead Electrocardiograph

The acquisition and interpretation of the ECG is the critical step for the diagnosis, triage and initiation of revascularisation therapy in patients with suspected high risk ACS and STEMI. This early recognition of STEMI patients has the potential to reduce delays to reperfusion and thus improve patient survival.

Therefore in patients with suspected ACS a 12 lead ECG should be acquired and interpreted in the pre-hospital emergency setting as soon as possible after first medical contact¹⁴⁻¹⁸. Acquisition and interpretation should then result in hospital notification of suspected STEMI with prehospital activation of the cardiac catheterisation laboratory if PPCI is the planned reperfusion strategy¹⁹ (CoSTR 2015, strong recommendation, low-quality evidence).

It is important that the system in place for the interpretation of the prehospital ECG has optimal diagnostic performance with low false positive and false negative rates. This is important to balance the risk of missing the diagnosis of STEMI against the costs of inappropriate activation of resources¹⁹. If the interpretation for pre-hospital usage is not available by medical staff by field transmission of the ECG for expert interpretation, then interpretation of the ECG by non-physicians trained in ECG interpretation is suggested²⁰⁻³² (CoSTR 2015, weak recommendation, very-low-quality evidence)¹⁹.

Further computer assisted interpretation of the ECG may be used as an adjunct or in conjunction to physician or non-physician interpretation in STEMI³³⁻³⁵. Whilst computer assisted ECG interpretation is highly specific for STEMI, it is not recommended that it be used as the sole strategy for ruling out STEMI as sensitivity is poor (CoSTR 2015, weak recommendation, very-low-quality evidence)¹⁹.

3.0 | Cardiac Biomarkers

All patients who present to the ED with symptoms suspicious of cardiac ischaemia should be evaluated with cardiac biomarkers as part of the initial evaluation^{36,37}. Cardiac specific troponin (cTnI or cTnT) has become the most widely utilized and validated diagnostic biomarker for myocardial infarction and is the preferred laboratory test. (LOE I). Given the burden of presentations of chest pain to emergency departments it is important to rule out the diagnosis of ACS to allow early appropriate discharge of patients. An acceptably low risk at 30 days is defined as a MACE event rate of <1%. To achieve such outcomes, cTn should not be used alone to exclude a diagnosis of ACS but should be combined with a validated clinical risk score (Vancouver rule, TIMI score, HEART score or North American Chest Pain rule) (CoSTR 2015, strong recommendation, very-low-quality evidence)¹⁹.

As cTn may be initially negative if the presentation is very soon after the symptom onset, it is

recommended paired biomarker testing (c TnI or c TnT) be performed at 0 and 3-6 hours after symptom onset and combined with a very low clinical risk score to reliably exclude myocardial necrosis³⁷⁻³⁹ (CoSTR 2015, weak recommendation, low-quality evidence)¹⁹.

Highly sensitive cardiac troponin assays (10% coefficient of cardiac variation at the 99th percentile) have been shown to have increased sensitivity and become positive at an earlier time after onset of ischaemia when compared to conventional assays⁴⁰⁻⁴³. This supports their use in the diagnosis of AMI. These assays are able to determine the presence of a positive biomarker reliably at 2 hours^{19,44,45}. (LOE II). A negative hs-cTnI at 0 and 2 hours combined with a low clinical risk score (Vancouver or TIMI score) can be used to exclude the diagnosis of ACS (CoSTR 2015, weak recommendation, low-quality evidence)¹⁹.

There has been a lack of evidence of supporting the routine use of point of care troponin testing in isolation as the primary test in a pre-hospital setting to evaluate patients with ACS⁴⁶.

It is important to note that not all troponin elevations are related to acute coronary syndromes.

Elevated troponin values have been described in a variety of conditions not at all related to acute coronary syndromes. These include myocarditis, pulmonary embolism, acute heart failure, septic shock, secondary to cardiotoxic drugs as well as after therapeutic procedures like coronary angioplasty, electrophysiological ablations, or electrical cardioversions⁴⁷.

There are a variety of biomarkers that have become available including myoglobin and brain natriuretic peptide (BNP), NT-proBNP, D-dimer, C-reactive protein, ischaemia-modified albumin, pregnancy-associated plasma protein A and interleukin 6. These tests however are not supported by sufficient evidence to allow their use in isolation to evaluate patients with symptoms or signs of myocardial ischaemia⁴⁸⁻⁵¹.

4.0 | Chest Pain Observation Units

The use of Chest Pain Observation Units (CPUs) and accelerated chest pain assessment pathways using protocols outlined above are recommended in the evaluation of patients with possible ACS. CPUs usually incorporate a protocol or pathway based strategy involving the measurement of serial biomarkers, serial ECG or continuous ECG monitoring to allow for a period of clinical observation integrated with more advanced diagnostic testing^{1,2,46,56-63}.

This strategy involving biomarker testing with associated protocols and pathways may be recommended as a means to reduce the length of stay, reduce hospital admissions, reduce health care costs and improve diagnostic accuracy in patients who are suspected as suffering ACS^{1,2,56-62}. (LOE III-1).

5.0 | Imaging Techniques

In patients with suspected ACS there are a variety of imaging techniques which may be utilised to diagnose acute coronary syndrome. These include CT angiography, MRI, nuclear cardiology

and echocardiography⁶⁴⁻⁷⁸. A non-invasive test may be considered in selective patients who present to the ED with chest pain and initial non-diagnostic conventional work-up. However it is important to consider both the exposure radiation and iodinated contrast when utilising these imaging modalities. (LOE II).

These non-invasive tests may help to improve the accuracy of the diagnosis and they may also, in select groups, decrease cost, length of stay and time of diagnosis. They may provide valuable short and long term prognostic information about the incidence of future major cardiac events⁶⁴⁻⁸⁴. (LOE II).

6.0 | Risk Stratification

There are a number of factors determined from the patient history, physical examination, initial ECG and biomarker testing, that allow the clinician to risk stratify patients. (LOE II).

The Australian indigenous, Maori and Pacific Islander population are at high risk for ischaemic heart disease and present at a younger age with more advanced disease⁸⁵. Features associated with high-risk, intermediate-risk and low-risk non-ST-segment-elevation acute coronary syndromes (NSTEMACS).

7.0 | High-risk Features

Presentation with clinical features consistent with acute coronary syndromes (ACS) and any of the following high-risk features⁸⁶:

- Repetitive or prolonged (> 10 minutes) ongoing chest pain or discomfort
- Elevated level of at least one cardiac biomarker (troponin or creatine kinase-MB isoenzyme)
- Persistent or dynamic electrocardiographic changes of ST-segment depression ≥ 0.5 mm or new T-wave inversion ≥ 2 mm
- Transient ST-segment elevation (≥ 0.5 mm) in more than two contiguous leads
- Haemodynamic compromise — systolic blood pressure < 90 mmHg, cool peripheries, diaphoresis, Killip Class > I, and/or new-onset mitral regurgitation
- Sustained ventricular tachycardia
- Syncope
- Left ventricular systolic dysfunction (left ventricular ejection fraction < 0.40)
- Prior percutaneous coronary intervention within 6 months or prior coronary artery bypass surgery
- Presence of known diabetes (with typical symptoms of ACS)
- Chronic kidney disease (estimated glomerular filtration rate < 60 mL/minute) (with typical symptoms of ACS).

8.0 | Intermediate-risk Features

Presentation with clinical features consistent with ACS and any of the following intermediate risk features AND NOT meeting the criteria for high-risk ACS:

- Chest pain or discomfort within the past 48 hours that occurred at rest, or was repetitive or prolonged (but currently resolved)
- Age > 65 years
- Known coronary heart disease — prior myocardial infarction with left ventricular ejection fraction ≥ 0.40 , or known coronary lesion more than 50% stenosed
- No high-risk changes on electrocardiography (see above)
- Two or more of the following risk factors: known hypertension, family history, active smoking or hyperlipidaemia
- Presence of known diabetes (with atypical symptoms of ACS)
- Chronic kidney disease (estimated glomerular filtration rate < 60 mL/minute) (with atypical symptoms of ACS)
- Prior aspirin use.

9.0 | Low-risk Features

Presentation with clinical features consistent with an acute coronary syndrome without intermediate-risk or high-risk features includes onset of angina symptoms within the last month, or worsening in severity or frequency of angina, or lowering of angina threshold.

A number of risk scores have been developed to assist in risk stratification using simple risk variables that can be calculated on information easily available to clinicians. These scores have been validated in large studies and predict major adverse cardiovascular outcomes in a robust fashion.

10.0 | The Thrombolysis in Myocardial Infarction (TIMI) score is one such score⁸⁷ (Table 1)

Predictor Variable	Point Value of Variable
Age ≥ 65 years	1
≥ 3 risk factors for CAD	1

Risk factors <ul style="list-style-type: none"> ● Family history of CAD ● Hypertension ● Hypercholesterolemia ● Diabetes ● Current smoker 	
Aspirin use in last 7 days	1
Recent, severe symptoms of angina <ul style="list-style-type: none"> ◦ ≥ 2 angina events in last 24 hours 	1
Elevated cardiac markers <ul style="list-style-type: none"> ◦ CK-MB or cardiac-specific troponin level 	1
ST deviation ≥ 0.5 mm	1
Prior coronary artery stenosis $\geq 50\%$	1

Calculated TIMI Risk Score:

Risk Status	Risk of ≥ 1 Primary End Point* in ≥ 14 Days
0 or 1	5% Low
2	8% Low
3	13% Intermediate
4	20% Intermediate
5	26% High

*Primary end points: death, new or recurrent MI, or need for urgent revascularization

Patients without high risk features may be managed with a conservative strategy that does not include routine invasive assessment with coronary angiography and PCI where indicated. (LOE I).

References

1. Goodacre SW, Angelini K, Arnold J, Revill S, Morris F. Clinical predictors of acute coronary syndromes in patients with undifferentiated chest pain. QJM 2003;96:893-8.
2. Goodacre S, Locker T, Morris F, Campbell S. How useful are clinical features in the diagnosis of acute, undifferentiated chest pain? Acad Emerg Med 2002;9:203-8.
3. Diercks DB, Boghos E, Guzman H, Amsterdam EA, Kirk JD. Changes in the numeric descriptive scale for pain after sublingual nitroglycerin do not predict cardiac etiology of

- chest pain. *Ann Emerg Med* 2005;45:581-5.
4. Shry EA, Dacus J, Van De Graaff E, Hjelkrem M, Stajduhar KC, Steinhubl SR. Usefulness of the response to sublingual nitroglycerin as a predictor of ischemic chest pain in the emergency department. *Am J Cardiol* 2002;90:1264-6.
 5. Steele R, McNaughton T, McConahy M, Lam J. Chest pain in emergency department patients: if the pain is relieved by nitroglycerin, is it more likely to be cardiac chest pain? *CJEM* 2006;8:164-9.
 6. Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease. *Annals of internal medicine* 2003;139:979-86.
 7. Panju AA, B.R. Hemmelgarn, G.G. Guyatt, and D.L. Simel. Is this patient having a myocardial infarction? *JAMA* 1998;280:1256-63.
 8. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. *The New England journal of medicine* 1996;334:1311-5.
 9. Solomon CG, Lee TH, Cook EF, et al. Comparison of clinical presentation of acute myocardial infarction in patients older than 65 years of age to younger patients: the Multicenter Chest Pain Study experience. *Am J Cardiol* 1989;63:772-6.
 10. Peberdy MA, Ornato JP. Coronary artery disease in women. *Heart Dis Stroke* 1992;1:315-9.
 11. Foraker RE, Rose KM, McGinn AP, et al. Neighborhood income, health insurance, and prehospital delay for myocardial infarction: the atherosclerosis risk in communities study. *Arch Intern Med* 2008;168:1874-9.
 12. Sari I, Acar Z, Ozer O, et al. Factors associated with prolonged prehospital delay in patients with acute myocardial infarction. *Turk Kardiyol Dern Ars* 2008;36:156-62.
 13. Jneid H, Fonarow GC, Cannon CP, et al. Sex differences in medical care and early death after acute myocardial infarction. *Circulation* 2008;118:2803-10.
 14. Banerjee S, Rhoden WE. Fast-tracking of myocardial infarction by paramedics. *J R Coll Physicians Lond* 1998;32:36-8.
 15. Melville MR, Gray D, al. e. The potential impact of prehospital electrocardiography and telemetry on time to thrombolysis in a United Kingdom center. *Ann Noninvasive Electrocardiol* 1998;3:327-33.
 16. Millar-Craig MW, Joy AV, Adamowicz M, Furber R, Thomas B. Reduction in treatment delay by paramedic ECG diagnosis of myocardial infarction with direct CCU admission. *Heart* 1997;78:456-61.
 17. Sandler DA. Paramedic direct admission of heart-attack patients to a coronary-care unit. *Lancet* 1998;352.
 18. Morrison LJ, Brooks S, Sawadsky B, McDonald A, Verbeek PR. Prehospital 12-lead electrocardiography impact on acute myocardial infarction treatment times and mortality: a systematic review. *Acad Emerg Med* 2006;13:84-9.
 19. Welsford M, Nikolaou NI, Beygui F, et al. Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Resuscitation* 2015;95:e121-46..
 20. Wall T, Albright J, Livingston B, et al. Prehospital ECG transmission speeds reperfusion for patients with acute myocardial infarction. *North Carolina Medical Journal* 2000;61:104-8.
 21. Terkelsen CJ, Jorgensen HA, Lassen JF, Norgaard BL, Gerdes JC, Andersen HR. [Telemedicine in prehospital remote diagnosis and re-routing of a patient with acute ST-elevation myocardial infarction to primary percutaneous coronary intervention]. *Ugeskr Laeger* 2003;165:4028-9.
 22. Terkelsen CJ, Lassen JF, Norgaard BL, Gerdes JC, Nielsen TT, Andersen HR. Are we underestimating the full potential of early thrombolytic treatment in patients with acute myocardial infarction? *Heart* 2003;89:483-4.
 23. Terkelsen CJ, Norgaard BL, Lassen JF, et al. Telemedicine used for remote prehospital diagnosing in patients suspected of acute myocardial infarction. *J Intern Med*

2002;252:412-20.

24. Swor R, Anderson W, Jackson R, Wilson A. Effects of EMS transportation on time to diagnosis and treatment of acute myocardial infarction in the emergency department. *Prehosp Disaster Med* 1994;9:160-4.
25. Swor R, Hegerberg S, McHugh-McNally A, Goldstein M, McEachin CC. Prehospital 12-lead ECG: efficacy or effectiveness? *Prehosp Emerg Care* 2006;10:374-7.
26. Takakuwa KM, Burek GA, Estepa AT, Shofer FS. A method for improving arrival-to-electrocardiogram time in emergency department chest pain patients and the effect on door-to-balloon time for ST-segment elevation myocardial infarction. *Acad Emerg Med* 2009;16:921-7.
27. Thorn S, Attali P, Boulenc JM, et al. [Delays of treatment of acute myocardial infarction with ST elevation admitted to the CCU (coronary care unit) in Alsace]. *Arch Mal Coeur Vaiss* 2007;100:7-12.
28. Trivedi K, Schuur JD, Cone DC. Can paramedics read ST-segment elevation myocardial infarction on prehospital 12-lead electrocardiograms? *Prehosp Emerg Care* 2009;13:207-14.
29. Vaught C, Young DR, Bell SJ, et al. The failure of years of experience with electrocardiographic transmission from paramedics to the hospital emergency department to reduce the delay from door to primary coronary intervention below the 90-minute threshold during acute myocardial infarction. *J Electrocardiol* 2006;39:136-41.
30. Youngquist ST, Shah AP, Niemann JT, Kaji AH, French WJ. A comparison of door-to-balloon times and false-positive activations between emergency department and out-of-hospital activation of the coronary catheterization team. *Acad Emerg Med* 2008;15:784-7.
31. Zalenski RJ, Rydman RJ, Sloan EP, Caceres L, Murphy DG, Cooke D. The emergency department electrocardiogram and hospital complications in myocardial infarction patients. *Acad Emerg Med* 1996;3:318-25.
32. Rao A, Kardouh Y, Darda S, et al. Impact of the prehospital ECG on door-to-balloon time in ST elevation myocardial infarction. *Catheter Cardiovasc Interv* 2010;75:174-8.
33. Adams GL, Campbell PT, Adams JM, et al. Effectiveness of prehospital wireless transmission of electrocardiograms to a cardiologist via hand-held device for patients with acute myocardial infarction (from the Timely Intervention in Myocardial Emergency, NorthEast Experience [TIME-NE]). *Am J Cardiol* 2006;98:1160-4.
34. Brown JP, Mahmud E, Dunford JV, Ben-Yehuda O. Effect of prehospital 12-lead electrocardiogram on activation of the cardiac catheterization laboratory and door-to-balloon time in ST-segment elevation acute myocardial infarction. *Am J Cardiol* 2008;101:158-61.
35. Clemmensen P, Sejersten M, Sillesen M, Hampton D, Wagner GS, Loumann-Nielsen S. Diversion of ST-elevation myocardial infarction patients for primary angioplasty based on wireless prehospital 12-lead electrocardiographic transmission directly to the cardiologist's handheld computer: a progress report. *J Electrocardiol* 2005;38:194-8.
36. Eggers KM, Oldgren J, Nordenskjold A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. *Am Heart J* 2004;148:574-81.
37. Jaffe AS, Apple FS, Morrow DA, Lindahl B, Katus HA. Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the definition of myocardial infarction. *Clin Chem* 2010;56:941-3.
38. Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. *Clin Chem* 2006;52:812-8.

39. Kavsak PA, Worster A, You JJ, et al. Identification of myocardial injury in the emergency setting. *Clin Biochem* 2010;43:539-44.
40. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *The New England journal of medicine* 2009;361:858-67.
41. Jaffe AS, Apple FS. High-sensitivity cardiac troponin: hype, help, and reality. *Clin Chem* 2010;56:342-4.
42. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. *Clin Chem* 2010;56:254-61.
43. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. *The New England journal of medicine* 2009;361:868-77.
44. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. *Eur Heart J* 2010;31:2197-204.
45. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. *Eur Heart J* 2012;33:2001-6.
46. O'Connor RE, Bossaert L, Arntz HR, et al. Part 9: acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation* 2010;122:S422-65.
47. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. *Annals of internal medicine* 2005;142:786-91.
48. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. *J Am Coll Cardiol* 2006;48:1-11.
49. Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. *Clin Chem* 2007;53:547-51.
50. Lee-Lewandrowski E, Januzzi JL, Green SM, et al. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. *Clin Chim Acta* 2007;386:20-4.
51. Apple FS, Jaffe AS. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. *Circulation* 2001;104:E125-6.
52. Chase M, Robey JL, Zogby KE, Sease KL, Shofer FS, Hollander JE. Prospective validation of the Thrombolysis in Myocardial Infarction Risk Score in the emergency department chest pain population. *Ann Emerg Med* 2006;48:252-9.
53. Pollack CV, Jr., Sites FD, Shofer FS, Sease KL, Hollander JE. Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population. *Acad Emerg Med* 2006;13:13-8.
54. Soiza RL, Leslie SJ, Williamson P, et al. Risk stratification in acute coronary syndromes--does the TIMI risk score work in unselected cases? *QJM* 2006;99:81-7.
55. Jaffery Z, Hudson MP, Jacobsen G, Nowak R, McCord J. Modified thrombolysis in myocardial infarction (TIMI) risk score to risk stratify patients in the emergency department with possible acute coronary syndrome. *J Thromb Thrombolysis* 2007;24:137-44.
56. Arnold J, Goodacre S, Morris F. Structure, process and outcomes of chest pain units established in the ESCAPE trial. *Emerg Med J* 2007;24:462-6.
57. Goodacre S, Morris F, Arnold J, Angelini K. Is a chest pain observation unit likely to be cost saving in a British hospital? *Emerg Med J* 2001;18:11-4.
58. Goodacre SW, Morris FM, Campbell S, Arnold J, Angelini K. A prospective, observational study of a chest pain observation unit in a British hospital. *Emerg Med J* 2002;19:117-21.
59. Stephenson DT, Wardrope JW, Goodacre SW. Is prehospital thrombolysis for acute

- myocardial infarction warranted in the urban setting? The case against. *Emerg Med J* 2002;19:444-7.
60. Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. *BMJ* 2004;328:254.
 61. Goodacre S, Turner J, Nicholl J. Prediction of mortality among emergency medical admissions. *Emerg Med J* 2006;23:372-5.
 62. Goodacre S, Cross E, Lewis C, Nicholl J, Capewell S. Effectiveness and safety of chest pain assessment to prevent emergency admissions: ESCAPE cluster randomised trial. *BMJ* 2007;335:659.
 63. Aroney CN, Dunlevie HL, Bett JH. Use of an accelerated chest pain assessment protocol in patients at intermediate risk of adverse cardiac events. *Med J Aust* 2003;178:370-4.
 64. Hansen M, Ginns J, Seneviratne S, et al. The value of dual-source 64-slice CT coronary angiography in the assessment of patients presenting to an acute chest pain service. *Heart Lung Circ* 2010;19:213-8.
 65. Santoro GM, Sciagra R, Buonamici P, et al. Head-to-head comparison of exercise stress testing, pharmacologic stress echocardiography, and perfusion tomography as first-line examination for chest pain in patients without history of coronary artery disease. *J Nucl Cardiol* 1998;5:19-27.
 66. Stowers SA, Eisenstein EL, Th Wackers FJ, et al. An economic analysis of an aggressive diagnostic strategy with single photon emission computed tomography myocardial perfusion imaging and early exercise stress testing in emergency department patients who present with chest pain but nondiagnostic electrocardiograms: results from a randomized trial. *Ann Emerg Med* 2000;35:17-25.
 67. Astarita C, Palinkas A, Nicolai E, Maresca FS, Varga A, Picano E. Dipyridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test. *J Hypertens* 2001;19:495-502.
 68. Ben-Gal T, Zafir N. The utility and potential cost-effectiveness of stress myocardial perfusion thallium SPECT imaging in hospitalized patients with chest pain and normal or non-diagnostic electrocardiogram. *Isr Med Assoc J* 2001;3:725-30.
 69. Conti A, Gallini C, Costanzo E, et al. Early detection of myocardial ischaemia in the emergency department by rest or exercise (99m)Tc tracer myocardial SPET in patients with chest pain and non-diagnostic ECG. *Eur J Nucl Med* 2001;28:1806-10.
 70. Gentile R, Vitarelli A, Schillaci O, et al. Diagnostic accuracy and prognostic implications of stress testing for coronary artery disease in the elderly. *Ital Heart J* 2001;2:539-45.
 71. Conti A, Paladini B, Magazzini S, et al. Chest pain unit management of patients at low and not low-risk for coronary artery disease in the emergency department. A 5-year experience in the Florence area. *Eur J Emerg Med* 2002;9:31-6.
 72. Conti A, Zanobetti M, Grifoni S, et al. Implementation of myocardial perfusion imaging in the early triage of patients with suspected acute coronary syndromes. *Nucl Med Commun* 2003;24:1055-60.
 73. Conti A, Sammiceli L, Gallini C, Costanzo EN, Antonucci D, Barletta G. Assessment of patients with low-risk chest pain in the emergency department: Head-to-head comparison of exercise stress echocardiography and exercise myocardial SPECT. *Am Heart J* 2005;149:894-901.
 74. Candell-Riera J, Oller-Martinez G, de Leon G, Castell-Conesa J, Aguade-Bruix S. Yield of early rest and stress myocardial perfusion single-photon emission computed tomography and electrocardiographic exercise test in patients with atypical chest pain, nondiagnostic electrocardiogram, and negative biochemical markers in the emergency department. *Am J Cardiol* 2007;99:1662-6.
 75. Rubinshtein R, Halon DA, Gaspar T, et al. Usefulness of 64-slice cardiac computed tomographic angiography for diagnosing acute coronary syndromes and predicting clinical

- outcome in emergency department patients with chest pain of uncertain origin. *Circulation* 2007;115:1762-8.
76. Sharples L, Hughes V, Crean A, et al. Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: a randomised controlled trial. The CECaT trial. *Health Technol Assess* 2007;11:iii-iv, ix-115.
 77. Bedetti G, Pasanisi EM, Pizzi C, Turchetti G, Lore C. Economic analysis including long-term risks and costs of alternative diagnostic strategies to evaluate patients with chest pain. *Cardiovasc Ultrasound* 2008;6:21.
 78. Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. *J Am Coll Cardiol* 2009;53:1642-50.
 79. Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. *Annals of internal medicine* 1999;130:719-28.
 80. Mowatt G, Vale L, Brazzelli M, et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. *Health Technol Assess* 2004;8:iii-iv, 1-207.
 81. Jeetley P, Burden L, Senior R. Stress echocardiography is superior to exercise ECG in the risk stratification of patients presenting with acute chest pain with negative Troponin. *Eur J Echocardiogr* 2006;7:155-64.
 82. Jeetley P, Hickman M, Kamp O, et al. Myocardial contrast echocardiography for the detection of coronary artery stenosis: a prospective multicenter study in comparison with single-photon emission computed tomography. *J Am Coll Cardiol* 2006;47:141-5.
 83. Jeetley P, Burden L, Greaves K, Senior R. Prognostic value of myocardial contrast echocardiography in patients presenting to hospital with acute chest pain and negative troponin. *Am J Cardiol* 2007;99:1369-73.
 84. Jeetley P, Burden L, Stoykova B, Senior R. Clinical and economic impact of stress echocardiography compared with exercise electrocardiography in patients with suspected acute coronary syndrome but negative troponin: a prospective randomized controlled study. *Eur Heart J* 2007;28:204-11.
 85. Brown A, Brieger D, Tonkin A, et al. Coronary disease in indigenous populations: summary from the CSANZ indigenous Cardiovascular Health Conference. *Heart Lung Circ* 2010;19:299-305.
 86. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. *Circulation* 2008;117:296-329.
 87. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. *JAMA* 2000;284:835-42.